The Silent Pandemic: Strategies to Combat Antimicrobial Resistance in India

1. Source and Context of the Call to Action

• Primary Reference. This analysis is based on the article by Ramya Kannan, “Fine-tune this signal to sharpen India’s AMR battle,” which can be accessed here: Source
• High-Level Recognition. On December 28, 2025, during the 129th edition of Mann Ki Baat, Prime Minister Narendra Modi officially categorized Antimicrobial Resistance (AMR) as a “matter of concern” for the nation.
• Mainstreaming the Crisis. Experts believe this prime-ministerial intervention acts as an anagnorisis—a moment of critical discovery—moving AMR from the specialized corridors of hospitals into the public consciousness.

2. The Core Driver: Irrational Antibiotic Use

• Indiscriminate Consumption. The Prime Minister highlighted the “thoughtless and indiscriminate use of antibiotics,” where citizens self-medicate or “pop a pill” for every minor ailment without medical consultation.
• Reduced Efficacy. Data from the Indian Council of Medical Research (ICMR) indicates that common antibiotics are becoming increasingly ineffective against life-threatening conditions like pneumonia and urinary tract infections (UTIs).
• The Advice. The government’s central message is a direct appeal to the population: “Avoid taking medicines by yourself, particularly antibiotics,” to prevent diseases from overpowering modern medicine.

3. Understanding the AMR Pathway

• Biological Mechanism. AMR occurs when bacteria, viruses, fungi, and parasites change over time and no longer respond to medicines, making infections harder to treat and increasing the risk of disease spread and death.
• The Misuse Cycle. Frequent, incomplete, or unnecessary doses of antibiotics kill weak bacteria but allow resistant strains to survive, multiply, and spread through the community.
• Human-Animal Link. Beyond human medicine, the overuse of antibiotics in livestock and poultry as “growth factors” (like the banned Colistin) significantly contributes to the environmental reservoir of resistant genes.

4. Limitations of Current Surveillance (NARS-Net)

• Network Scope. India’s National AMR Surveillance Network (NARS-Net) currently comprises 60 sentinel laboratories, primarily located in government medical colleges.
• Reporting Gaps. In the 2023 WHO GLASS report, only 41 sites across 31 States/UTs successfully provided data, suggesting inconsistencies in reporting and laboratory capacity.
• Pathogen Priority. The network is tasked with tracking nine priority bacterial pathogens of public health importance, but the current data reflects only a fraction of India’s vast geography.

5. The Urban-Tertiary Care Bias

• Skewed Data. Current surveillance sites are concentrated in urban centers and tertiary care hospitals, which often treat the most severe, drug-resistant cases.
• Missing Communities. There is a lack of data from secondary and primary care centers, meaning the current statistics may not accurately reflect the community-level prevalence of AMR in rural India.
• The Balanced Picture. Experts argue that until non-urban data is integrated, the national resistance picture remains distorted, potentially overestimating or underestimating the true threat.

6. Expanding the Surveillance Network

• Inclusive Integration. Specialists like Dr. Abdul Ghafur have urged the National Centre for Disease Control (NCDC) to include private hospitals and primary health centers in the national network.
• Representing Variance. Given India’s wide geographical and socio-economic variance, surveillance must be expanded to provide an exhaustive and representative national dataset.
• Investment Needs. Expanding this network requires significant capital investment in laboratory infrastructure, digital data-sharing tools, and trained personnel.

7. The “One Health” Approach

• Interconnected Health. AMR is a “hydra-headed beast” that cannot be solved by human medicine alone; it requires a “One Health” approach that integrates human, animal, and environmental health strategies.
• Environmental Impact. Runoff from pharmaceutical manufacturing hubs and untreated hospital waste often contains high concentrations of antibiotic residues, turning water bodies into breeding grounds for superbugs.
• Policy Alignment. Solutions must simultaneously address agricultural practices, sanitation, and medical prescriptions to effectively “behead” the monster of resistance.

8. WHO’s Five Strategic Objectives

• Awareness and Education. Improving the understanding of AMR through effective communication and training.
• Surveillance and Research. Strengthening the knowledge and evidence base through a robust national network.
• Sanitation and Hygiene. Reducing the incidence of infection through effective sanitation and infection prevention measures.
• Optimizing Use. Ensuring that antimicrobial agents are used only when necessary and in the correct dosages.
• Sustainable Investment. Encouraging the development of new medicines, diagnostic tools, and vaccines.

9. Barriers to Implementation in India

• Over-the-Counter (OTC) Culture. Despite regulations, antibiotics remain easily accessible without prescriptions in many parts of the country due to weak enforcement at pharmacies.
• Diagnostic Costs. High costs and long turnaround times for diagnostic tests often lead doctors to prescribe “broad-spectrum” antibiotics empirically rather than targeted treatments.
• Political Will. While public awareness is growing, the “monitoring and enforcement” aspect of AMR policy requires sustained political courage to regulate powerful pharmaceutical and poultry sectors.

10. The Path Forward: Beyond Awareness

• Translating Speech to Action. While the PM’s speech is a vital starting point, it must be followed by stringent regulatory changes and a massive scale-up of the surveillance apparatus.
• Behavioral Change. Success depends on whether listeners treat the advice to “avoid self-medication” as a religious practice rather than a temporary suggestion.
• Global Contribution. By sharpening its domestic battle against AMR, India—often called the “pharmacy of the world”—can play a decisive role in the global survival against drug-resistant infections.